NCT00815607 - Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

Melanoma

Interventions

DRUG

INXN-1001

Capsules given once daily for 14 days for 3 treatment cycles.

BIOLOGICAL

INXN-3001

Intratumoral injection

Trial Locations (8)

Penn State Milton S. Hershey Medical Center, Hershey

Helen F. Graham Cancer Center, Newark

• Nancy N. and J.C. Lewis Cancer Center & Research Pavilion at St. Joseph/Candles, Savannah

Goshen Clinic, Goshen

Billings Clinic, Billings

Oncology Specialists, S.C., Park Ridge

Mary Crowley Cancer Research Centers, Dallas

The Angeles Clinic and Research Institute, Santa Monica